Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01497704

Dose-Escalation and Safety Trial of YN968D1

Evaluation of the Safety, Pharmacokinetics and Efficacy of Four Doses of YN968D1 in Subjects With Solid Tumors

Sponsor: Bukwang Pharmaceutical, Co., Ltd.

Conditions Cancer Patients With Solid Tumors

Interventions YN968D1

Updated 10 times since 2017 Last updated: Sep 26, 2017 Started: Apr 30, 2012 Primary completion: Feb 28, 2015 Completion: May 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01497704, this PHASE1/PHASE2 trial focuses on Cancer Patients With Solid Tumors and remains completed. Sponsored by Bukwang Pharmaceutical, Co., Ltd., it has been updated 10 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE1_PHASE2

▶ Show 5 earlier versions

Mar 2020 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Mar 2020 [monthly]

Completed PHASE1_PHASE2
Apr 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Apr 2017 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Apr 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bukwang Pharmaceutical, Co., Ltd.
Elevar Therapeutics

Data source: Elevar Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Salt Lake City, United States
• Seoul, South Korea